InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,845.60
(
0.88%
)
Post# of 10489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

MDMSCF

Send PM Follow Ignore
Followers 0
Posts 37
Boards Moderated 0
Alias Born 10/16/2013

MDMSCF

Re: None

Saturday, 12/27/2014 11:32:32 AM

Saturday, December 27, 2014 11:32:32 AM

Post# of 10489
NeuVax Phase 3 Trial. By my estimates, over 670 have enrolled and 38-40 control patients have had their Cancer recur. Since the interim results (70 recurrence events) have not been released yet, it means NeuVax is at least demonstrating a 25% reduction in recurrence. We only need a 30% improvement in DFS for approval.

Every week from here on out that the interim results are not released increased the DFS for NeuVax patients!

I'm certainly looking forward to 2015.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up